Fan Yu-Min, Chen Jian-Syun, Kuo Hsiao-Li, Chen Tzu-Chien, Wang Kung-Liahng, Chen Jen-Ruei
Department of Obstetrics and Gynecology, MacKay Memorial Hospital, Taipei City, Taiwan.
Division of Colon and Rectal Surgery, Department of Surgery, MacKay Memorial Hospital, Taipei City, Taiwan.
Taiwan J Obstet Gynecol. 2025 Sep;64(5):796-801. doi: 10.1016/j.tjog.2025.05.015.
The gold standard for treating primary advanced ovarian, primary peritoneal, and fallopian tubal cancers (OC) is optimal debulking surgery plus adjuvant chemotherapy. Neoadjuvant chemotherapy followed by optimal interval debulking surgery (NACT/IDS) with hyperthermic intraperitoneal chemotherapy (HIPEC) provides better survival outcomes than without HIPEC in current literature. The modeled CA-125 elimination rate constant k (KLEM) score reflects the response of NACT before IDS. A BRCA mutation may indicate a better response to chemotherapy and improved outcomes in OC. However, the correlation between these two factors and the completeness of cytoreduction (CC) during IDS/HIPEC has been less extensively discussed.
We retrospectively enrolled 17 HIPEC cases, including 10 NACT/IDS and seven secondary cytoreductive surgery (SCS) cases after database searching and chart review. The KELIM score was calculated in the NACT/IDS group for predicting the residual status of surgery.
The survivorship between NACT/IDS and SCS was similar. There is no major surgical complication, morbidity or mortality after HIPEC. In the IDS group, five cases reached CC scores of 0 (however, two of these cases had an unfavorable KELIM score), four cases reached a CC of 1, and one case had a CC of 2, but with a favorable KELIM score. In the SCS group, three cases reached a CC of 0, two reached a CC of 1, and two reached a CC of 2. There was no serious post-operative morbidity or mortality after HIPEC. The KELIM score showed a weak correlation with the CC score. Two cases with BRCA 1/2 mutation showed unfavorable KELIM scores and only one case reached CC of 0.
After the maturation of the HIPEC techniques, this procedure is safe and feasible. Currently, there are no reliable pre-operative markers, including KELIM score or BRCA1/2 status, which could predict the CC score after surgery.
治疗原发性晚期卵巢癌、原发性腹膜癌和输卵管癌(OC)的金标准是最佳减瘤手术加辅助化疗。在当前文献中,新辅助化疗后行最佳间隔减瘤手术(NACT/IDS)并联合热灌注腹腔化疗(HIPEC)比不进行HIPEC能提供更好的生存结果。模拟的CA-125消除率常数k(KLEM)评分反映了IDS前NACT的反应。BRCA突变可能表明对化疗反应更好且OC患者预后改善。然而,这两个因素与IDS/HIPEC期间的细胞减灭术完整性(CC)之间的相关性较少被广泛讨论。
通过数据库检索和病历审查,我们回顾性纳入了17例HIPEC病例,包括10例NACT/IDS病例和7例二次细胞减灭术(SCS)病例。在NACT/IDS组中计算KELIM评分以预测手术残留状态。
NACT/IDS组和SCS组的生存率相似。HIPEC后无重大手术并发症、发病率或死亡率。在IDS组中,5例达到CC评分为0(然而,其中2例KELIM评分不佳),4例达到CC为1,1例达到CC为2,但KELIM评分良好。在SCS组中,3例达到CC为0,2例达到CC为1,2例达到CC为2。HIPEC后无严重术后发病率或死亡率。KELIM评分与CC评分呈弱相关。2例BRCA 1/2突变病例KELIM评分不佳,仅1例达到CC为0。
HIPEC技术成熟后,该手术安全可行。目前,尚无可靠的术前标志物,包括KELIM评分或BRCA1/2状态,可预测术后CC评分。